|
1
|
Hundal HS, Ramlal T, Reyes R, Leiter LA
and Klip A: Cellular mechanism of metformin action involves glucose
transporter translocation from an intracellular pool to the plasma
membrane in L6 muscle cells. Endocrinology. 131:1165–1173. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dowling RJ, Goodwin PJ and Stambolic V:
Understanding the benefit of metformin use in cancer treatment. BMC
Med. 9:332011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shank JJ, Yang K, Ghannam J, Cabrera L,
Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets
ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol.
127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rattan R, Ali Fehmi R and Munkarah A:
Metformin: An emerging new therapeutic option for targeting cancer
stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Jiao M, Li L, Wu D, Wu K, Li X,
Zhu G, Dang Q, Wang X, Hsieh JT and He D: Tumorspheres derived from
prostate cancer cells possess chemoresistant and cancer stem cell
properties. J Cancer Res Clin Oncol. 138:675–686. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen G, Xu S, Renko K and Derwahl M:
Metformin inhibits growth of thyroid carcinoma cells, suppresses
self-renewal of derived cancer stem cells, and potentiates the
effect of chemotherapeutic agents. J Clin Endocrinol Metab.
97:E510–E520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung JW, Park SB, Lee SJ, Seo MS, Trosko
JE and Kang KS: Metformin represses self-renewal of the human
breast carcinoma stem cells via inhibition of estrogen
receptor-mediated OCT4 expression. PLoS One. 6:e280682011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufi S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin
regulates breast cancer stem cell ontogeny by transcriptional
regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cufí S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to-mesenchymal transition
(EMT): From cancer stem cells to aging-associated fibrosis. Cell
Cycle. 9:4461–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang
Y, Deng J, Margolick JB, Liotta LA, Petricoin E III and Zhang Y:
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer
stem-like cells is required for viability and maintenance. Proc
Natl Acad Sci USA. 104:16158–16163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chun SY, Kwon YS, Nam KS and Kim S:
Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7
tumorspheres by inhibiting the drug efflux function of ABC
transporters. Biomed Pharmacother. 72:37–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim S and Alexander CM: Tumorsphere assay
provides more accurate prediction of in vivo responses to
chemotherapeutics. Biotechnol Lett. 36:481–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwon YS, Chun SY, Nam KS and Kim S:
Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to
doxorubicin by inhibiting the expression of multidrug
resistance-associated protein-1. Oncol Rep. 34:884–890. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Calvet CY, André FM and Mir LM: The
culture of cancer cell lines as tumorspheres does not
systematically result in cancer stem cell enrichment. PLoS One.
9:e896442014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pastrana E, Silva-Vargas V and Doetsch F:
Eyes wide open: A critical review of sphere-formation as an assay
for stem cells. Cell Stem Cell. 8:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guttilla IK, Phoenix KN, Hong X, Tirnauer
JS, Claffey KP and White BA: Prolonged mammosphere culture of MCF-7
cells induces an EMT and repression of the estrogen receptor by
microRNAs. Breast Cancer Res Treat. 132:75–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manuel Iglesias J, Beloqui I,
Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, Cufi S, Pavon
A, Menendez JA, Dopazo J and Martin AG: Mammosphere formation in
breast carcinoma cell lines depends upon expression of E-cadherin.
PLoS One. 8:e772812013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uchida Y, Tanaka S, Aihara A, Adikrisna R,
Yoshitake K, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Irie
T, et al: Analogy between sphere forming ability and stemness of
human hepatoma cells. Oncol Rep. 24:1147–1151. 2010.PubMed/NCBI
|
|
30
|
Li L and Bhatia R: Stem cell quiescence.
Clin Cancer Res. 17:4936–4941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moore N and Lyle S: Quiescent,
slow-cycling stem cell populations in cancer: A review of the
evidence and discussion of significance. J Oncol. 2011:3960762011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eyler CE, Foo WC, LaFiura KM, McLendon RE,
Hjelmeland AB and Rich JN: Brain cancer stem cells display
preferential sensitivity to Akt inhibition. Stem Cells.
26:3027–3036. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Korkaya H, Paulson A, Charafe-Jauffret E,
Ginestier C, Brown M, Dutcher J, Clouthier SG and Wicha MS:
Regulation of mammary stem/progenitor cells by
PTEN/Akt/beta-catenin signaling. PLoS Biol. 7:e10001212009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kalender A, Selvaraj A, Kim SY, Gulati P,
Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et
al: Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway
is required for growth of CD44+CD24+ stem
cell-like breast cancer cells in human tumors. J Clin Invest.
121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei W, Tweardy DJ, Zhang M, Zhang X,
Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM and
Lewis MT: STAT3 signaling is activated preferentially in
tumor-initiating cells in claudin-low models of human breast
cancer. Stem Cells. 32:2571–2582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matsuda T, Nakamura T, Nakao K, Arai T,
Katsuki M, Heike T and Yokota T: STAT3 activation is sufficient to
maintain an undifferentiated state of mouse embryonic stem cells.
EMBO J. 18:4261–4269. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raz R, Lee CK, Cannizzaro LA, d'Eustachio
P and Levy DE: Essential role of STAT3 for embryonic stem cell
pluripotency. Proc Natl Acad Sci USA. 96:2846–2851. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Iliopoulos D, Hirsch HA, Wang G and Struhl
K: Inducible formation of breast cancer stem cells and their
dynamic equilibrium with non-stem cancer cells via IL6 secretion.
Proc Natl Acad Sci USA. 108:1397–1402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng XS, Wang S, Deng A, Liu B, Edgerton
SM, Lind SE, Wahdan-Alaswad R and Thor AD: Metformin targets Stat3
to inhibit cell growth and induce apoptosis in triple-negative
breast cancers. Cell Cycle. 11:367–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
